Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings.
Caffeine base
Caffeine citrate
Chemical compatibility
Neonates
Physical compatibility
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
28 Mar 2024
28 Mar 2024
Historique:
received:
18
02
2024
accepted:
19
03
2024
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
28
3
2024
Statut:
aheadofprint
Résumé
To investigate the physicochemical compatibility of caffeine citrate and caffeine base injections with 43 secondary intravenous (IV) drugs used in Neonatal Intensive Care Unit (NICU) settings. Caffeine citrate (20 mg/mL or 10 mg/mL) or caffeine base injection (10 mg/mL) were mixed in a volume ratio of 1:1 with the secondary drug solution to simulate Y-site co-administration procedures in NICUs. Physical compatibility was evaluated based on visual observation for 2 h, against a black and white background and under polarised light, for changes in colour, precipitation, haze and evolution of gas. Chemical compatibility was determined from caffeine concentration measurements, using a validated high-performance liquid chromatography assay. Six of the 43 secondary drugs tested (aciclovir, amphotericin (liposomal), furosemide, hydrocortisone, ibuprofen and ibuprofen lysine) were physically incompatible with caffeine citrate undiluted injection (20 mg/mL), at their high-end, clinically relevant concentrations for NICU settings. However, when tested at lower concentrations, hydrocortisone (1 mg/mL) was physicochemically compatible, whereas furosemide (0.2 mg/mL) was physically incompatible with caffeine citrate. The six drugs which showed physical incompatibility with caffeine citrate 20 mg/mL injection were also physically incompatible with caffeine citrate 10 mg/mL solution. All 43 secondary drugs tested were physicochemically compatible with caffeine base injection. Most secondary test drugs, except aciclovir, amphotericin (liposomal), furosemide, hydrocortisone, ibuprofen and ibuprofen lysine, were physicochemically compatible with caffeine citrate injection. Caffeine base injection was physicochemically compatible with all 43 test drugs tested.
Identifiants
pubmed: 38546840
doi: 10.1007/s00228-024-03678-6
pii: 10.1007/s00228-024-03678-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Mathew OP (2011) Apnea of prematurity: pathogenesis and management strategies. J Perinatol 31:302–310. https://doi.org/10.1038/jp.2010.126
doi: 10.1038/jp.2010.126
pubmed: 21127467
Bhatt-Mehta V, Schumacher RE (2003) Treatment of apnea of prematurity. Paediatr Drugs 5:195–210. https://doi.org/10.2165/00128072-200305030-00006
doi: 10.2165/00128072-200305030-00006
pubmed: 12608884
Bairam A, Boutroy MJ, Badonnel Y, Vert P (1987) Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. J Pediatr 110:636–639. https://doi.org/10.1016/s0022-3476(87)80569-3
doi: 10.1016/s0022-3476(87)80569-3
pubmed: 3559816
Brouard C, Moriette G, Murat I, Flouvat B, Pajot N, Walti H, de Gamarra E, Relier J-P (1985) Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. Am J Dis Child 139:698–700. https://doi.org/10.1001/archpedi.1985.02140090060028
doi: 10.1001/archpedi.1985.02140090060028
pubmed: 4014092
Erenberg A, Leff RD, Haack DG, Mosdell KW, Hicks GM, Wynne BA (2000) Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study. Pharmacotherapy 20:644–652. https://doi.org/10.1592/phco.20.7.644.35167
doi: 10.1592/phco.20.7.644.35167
pubmed: 10853619
Moschino L, Zivanovic S, Hartley C, Trevisanuto D, Baraldi E, Roehr CC (2020) Caffeine in preterm infants: where are we in 2020? ERJ Open Res 6:00330–02019. https://doi.org/10.1183/23120541.00330-2019
doi: 10.1183/23120541.00330-2019
pubmed: 32154294
pmcid: 7049734
Aranda JV, Cook CE, Gorman W, Collinge JM, Loughnan PM, Outerbridge EW, Aldridge A, Neims AH (1979) Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J Pediatr 94:663–668. https://doi.org/10.1016/s0022-3476(79)80047-5
doi: 10.1016/s0022-3476(79)80047-5
pubmed: 430317
Davis J, Spitzer A, Stefano J, Bhutani V, Fox W (1987) Use of caffeine in infants unresponsive to theophylline in apnea of prematurity. Pediatr Pulmonol 3:90–93. https://doi.org/10.1002/ppul.1950030210
doi: 10.1002/ppul.1950030210
pubmed: 3588062
Dobson NR, Hunt CE (2013) Pharmacology review: caffeine use in neonates: indications, pharmacokinetics, clinical effects, outcomes. NeoReviews 14:e540–e550. https://doi.org/10.1542/neo.14-11-e540
doi: 10.1542/neo.14-11-e540
King Edward Memorial Hospital - Clinical Neonatal Medication Protocols. https://www.kemh.health.wa.gov.au/For-Health-Professionals/Clinical-Guidelines/Neonatal . Accessed 16 Jul 2023
Pettit J (2002) Assessment of infants with peripherally inserted central catheters: part 1. Detecting the most frequently occurring complications. Adv Neonatal Care 2:304–315. https://doi.org/10.1053/adnc.2002.36826
doi: 10.1053/adnc.2002.36826
pubmed: 12881943
O’Brien F, Clapham D, Krysiak K, Batchelor H, Field P, Caivano G, Pertile M, Nunn A, Tuleu C (2019) Making medicines baby size: the challenges in bridging the formulation gap in neonatal medicine. Int J Mol Sci 20:2688. https://doi.org/10.3390/ijms20112688
doi: 10.3390/ijms20112688
pubmed: 31159216
pmcid: 6600135
Sherwin CMT, Medlicott NJ, Reith DM, Broadbent RS (2014) Intravenous drug delivery in neonates: lessons learnt. Arch Dis Child 99:590–594. https://doi.org/10.1136/archdischild-2013-304887
doi: 10.1136/archdischild-2013-304887
pubmed: 24482352
Parikh MJ, Dumas G, Silvestri A, Bistrian BR, Driscoll DF (2005) Physical compatibility of neonatal total parenteral nutrient admixtures containing organic calcium and inorganic phosphate salts. Am J Health Syst Pharm 62:1177–1183. https://doi.org/10.1093/ajhp/62.11.1177
doi: 10.1093/ajhp/62.11.1177
pubmed: 15914878
Mitchell A, Gailey R (1999) Compatibility of caffeine citrate with other medications commonly used in a neonatal intensive care unit. J Pediatr Pharm Pract 4:239–242
Audet M-A, Forest E, Friciu M, Forest J-M, Leclair G (2017) Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 50:27–33
American Society of Health-System Pharmacists (2022) ASHP injectable drug information: a comprehensive guide to compatibility and stability. American Society of Health-System Pharmacists: Bethesda (MD), pp 230–232
Nahata MC, Zingarelli JR, Durrell DE (1989) Stability of caffeine injection in intravenous admixtures and parenteral nutrition solutions. DICP 23:466–467. https://doi.org/10.1177/106002808902300606
doi: 10.1177/106002808902300606
pubmed: 2500782
Oliphant EA, Purohit TJ, Alsweiler JM, McKinlay CJ, Hanning SM (2022) Validation and application of a simple and rapid stability-indicating liquid chromatographic assay for the quantification of caffeine from human saliva. J Liq Chromatogr Relat Technol 45:10–17. https://doi.org/10.1080/10826076.2022.2095402
doi: 10.1080/10826076.2022.2095402
European Medicines Agency (1995) ICH Topic Q 2 (R1) Validation of analytical procedures: text and methodology. European Medicines Agency: London (UK)
Allen LV Jr, Levinson RS, Phisutsinthop D (1977) Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm 34:939–943. https://doi.org/10.1093/ajhp/34.9.939
doi: 10.1093/ajhp/34.9.939
pubmed: 20779
Akkerman SR, Zhang H, Mullins RE, Yaughn K (1999) Stability of milrinone lactate in the presence 29 critical care drugs and 4 i.v. solutions. Am J Health Syst Pharm 56:63–68. https://doi.org/10.1093/ajhp/56.1.63
doi: 10.1093/ajhp/56.1.63
pubmed: 10048881
Anderson C, Boehme S, Ouellette J, Stidham C, Mackay M (2014) Physical and chemical compatibility of injectable acetaminophen during simulated Y-site administration. Hosp Pharm 49:42–47. https://doi.org/10.1310/hpj4901-42
doi: 10.1310/hpj4901-42
pubmed: 24421562
pmcid: 3887589
Bell MS, Nolt DH (2003) Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery Am J Health Syst Pharm 60:193–194. https://doi.org/10.1093/ajhp/60.2.193
doi: 10.1093/ajhp/60.2.193
Luu Y, Thigpen J, Brown SD (2017) Stability of sildenafil in combination with heparin and dopamine. Am J Health Syst Pharm 74:e64–e71. https://doi.org/10.2146/ajhp150853
doi: 10.2146/ajhp150853
pubmed: 28007723
AlSalman F, Howlett M, Breatnach C, Kelly H, O’Brien F (2020) Supporting the use of sildenafil infusions in paediatric and neonatal intensive care – a compatibility study. Eur J Pharm Biopharm 151:153–161. https://doi.org/10.1016/j.ejpb.2020.04.008
doi: 10.1016/j.ejpb.2020.04.008
pubmed: 32289494
Knudsen L, Eisend S, Haake N, Kunze T (2014) Physicochemical compatibility of commonly used analgesics and sedatives in the intensive care medicine. Eur J Hosp Pharm 21:161–166. https://doi.org/10.1136/ejhpharm-2014-000444
doi: 10.1136/ejhpharm-2014-000444
Koller AK, Krebs S, Dorje F (2020) Medication safety in intravenous therapy: a compatibility study of clonidine with drugs frequently used in intensive care. Pharmaceutics 13:21. https://doi.org/10.3390/pharmaceutics13010021
doi: 10.3390/pharmaceutics13010021
pubmed: 33374362
pmcid: 7824220
Latheef F, Wahlgren H, Lilja HE, Diderholm B, Paulsson M (2021) The risk of necrotizing enterocolitis following the administration of hyperosmolar enteral medications to extremely preterm infants. Neonatology 118:73–79. https://doi.org/10.1159/000513169
doi: 10.1159/000513169
pubmed: 33567438
Lessard J-J, Caron E, Scherer H, Forest J-M, Leclair G (2020) Compatibility of Y-site injection of meropenem trihydrate with 101 other injectable drugs. Hosp Pharm 55:332–337. https://doi.org/10.1177/0018578719844168
doi: 10.1177/0018578719844168
pubmed: 32999503
Holt RJ, Siegert SWK, Krishna A (2008) Physical compatibility of ibuprofen lysine injection with selected drugs during simulated Y-site injection. J Pediatr Pharmacol Ther 13:156–161. https://doi.org/10.5863/1551-6776-13.3.156
doi: 10.5863/1551-6776-13.3.156
pubmed: 23055876
pmcid: 3462039
Veltri MA, Conner KG (2002) Physical compatibility of milrinone lactate injection with intravenous drugs commonly used in the pediatric intensive care unit. Am J Health Syst Pharm 59:452–454. https://doi.org/10.1093/ajhp/59.5.452
doi: 10.1093/ajhp/59.5.452
pubmed: 11887412
Humbert-delaloye V, Berger-gryllaki M, Voirol P, Gattlen L, Pannatier A (2013) In vitro compatibility of various cardioactive drugs during simulated Y-site administration. Eur J Hosp Pharm 20:110–116. https://doi.org/10.1136/ejhpharm-2012-000239
doi: 10.1136/ejhpharm-2012-000239
Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A (2015) Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide. Eur J Hosp Pharm 22:56–58. https://doi.org/10.1136/ejhpharm-2013-000431
doi: 10.1136/ejhpharm-2013-000431
Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F (2015) Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. Eur J Hosp Pharm 22:123–124. https://doi.org/10.1136/ejhpharm-2014-000478
doi: 10.1136/ejhpharm-2014-000478
Senarathna SMDKG, Strunk T, Petrovski M, Batty KT (2019) Physical compatibility of pentoxifylline and intravenous medications. Arch Dis Child 104:292–295. https://doi.org/10.1136/archdischild-2018-315376
doi: 10.1136/archdischild-2018-315376
pubmed: 30472662
Veltri M, Lee CKK (1996) Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health Syst Pharm 53:2611–2613. https://doi.org/10.1093/ajhp/53.21.2611
doi: 10.1093/ajhp/53.21.2611
pubmed: 8913390
De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, Lopez-Gimenez LR, Pascual P, De Miguel M, Campino A (2021) Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pediatr 180:1169–1176. https://doi.org/10.1007/s00431-020-03854-7
doi: 10.1007/s00431-020-03854-7
pubmed: 33128625
Kanji S, Lam J, Johanson C, Singh A, Goddard R, Fairbairn J, Lloyd T, Monsour D, Kakal J (2010) Systematic review of physical and chemical compatibility of commonly used medications administered by continuous infusion in intensive care units. Crit Care Med 38:1890–1898. https://doi.org/10.1097/CCM.0b013e3181e8adcc
doi: 10.1097/CCM.0b013e3181e8adcc
pubmed: 20562698